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Abstract 
Background and purpose: Prostaglandin E2 (PGE2) has been shown to inhibit 
cytokine generation from human lung macrophages.  However, the EP receptor that 
mediates this beneficial anti-inflammatory effect of PGE2 has not been elucidated 
definitively.  The aim of this study was to identify the EP receptor by which PGE2 
inhibits cytokine generation from human lung macrophages.  This was determined by 
using recently-developed EP receptor ligands. 
Experimental approach: The effects of PGE2 and EP-selective agonists on 
lipopolysaccharide (LPS) induced tumour necrosis factor-Į71)ĮDQGLQWHUOHXNLQ-6 
(IL-6) generation from macrophages were evaluated.  The effects of EP2-selective 
(PF-04852946, PF-04418948) and EP4-selective (L-161,982, CJ-042794) antagonists 
on PGE2 responses were studied.  The expression of EP receptor subtypes by human 
lung macrophages was determined by RT-PCR. 
Key results: PGE2 inhibited LPS-induced and Streptococcus pneumoniae-induced 
cytokine generation from human lung macrophages.  Analysis of mRNA levels 
indicated that macrophages expressed EP2 and EP4 receptors.  L-902,688 (EP4-
selective agonist) was considerably more potent than butaprost (EP2-selective agonist) 
DVDQLQKLELWRURI71)ĮJHQHUDWLRQIURPPDFURSKDJHV(32-selective antagonists had 
marginal effects on the PGE2 LQKLELWLRQRI71)ĮJHQHUDWLRQZKHUHDV(34-selective 
antagonists caused rightward shifts in the PGE2 concentration-response curves.  
Conclusions and implications: These studies demonstrate that the EP4 receptor is the 
principal receptor that mediates the anti-inflammatory effects of PGE2 on human lung 
macrophages.  This suggests that EP4 agonists could be effective anti-inflammatory 
agents in human lung disease. 
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Abbreviations 
COPD, chronic obstructive pulmonary disease  
FCS, foetal calf serum 
IL-6, interleukin-6   
LPS, lipopolysaccharide  
PBS, phosphate buffered saline 
PDE, phosphodiesterase  
PGE2, prostaglandin E2;  
RT-PCR, reverse transcription-polymerase chain reaction 
71)Į, tumour necrosis factor-Į 
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Introduction 
Prostaglandin E2 (PGE2) is known to have wide-ranging effects on a variety of 
tissues. These effects of PGE2 are mediated through specific EP receptors of which 
four have been identified (Coleman et al., 1994; Breyer et al., 2001; Woodward et al., 
2011). In the lung, PGE2 can act on airway smooth muscle to mediate 
bronchodilation.  This had led to suggestions that targeting EP receptors may be of 
benefit in the treatment of respiratory diseases (Kawakami et al., 1973; Melillo et al., 
1994; Gauvreau et al., 1999).  An undesirable effect of PGE2, however, is that it also 
induces cough (Maher et al., 2011).  Nonetheless, cough and bronchodilation appear 
to be mediated by different receptors suggesting that selective targeting of the 
beneficial receptor might be possible.  The EP3 receptor has been linked to cough 
(Maher et al., 2011) whereas bronchodilation appears to be mediated by EP4 receptors 
(Buckley et al., 2011; Benyahia et al., 2012).  Identification of the relevant EP 
receptor that mediates the beneficial effects of PGE2 is likely to be valuable 
information from a clinical perspective.  
The human lung macrophage plays an important role in host defence in the 
lung.  However, aberrant activation of lung macrophages has been linked to 
respiratory diseases, chronic obstructive pulmonary disease (COPD) in particular 
(Barnes, 2008).  PGE2 has been shown to inhibit pro-inflammatory cytokine release 
from lung macrophages (Rowe et al., 1997; Ratcliffe et al., 2007; Buenestado et al., 
2012).  This effect of PGE2 on human lung macrophages has been reported to be 
mediated by EP2 and EP4 receptors (Ratcliffe et al., 2007).  However, this conclusion 
was drawn at a time when the availability of selective pharmacological ligands at EP2 
and EP4 receptors was limited.  The situation has now changed with the recent 
emergence of novel ligands such as PF-04418948, the first potent and selective EP2 
receptor antagonist reported (af Forselles et al., 2011).  Use of these novel 
experimental tools has provided an opportunity to reappraise the mechanism by which 
PGE2 stabilizes macrophage responses.  In this regard, use of these tools has shown 
that the EP4 receptor is the main receptor regulating functional responses in THP-1 
cells, a human monocytic cell line (Birrell et al., 2015). 
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 The aim of the present study was to identify the EP receptor responsible for 
mediating the inhibitory effects of PGE2 on pro-inflammatory cytokine release from 
human lung macrophages  This was determined by using a variety of pharmacological 
ligands, principally, a range of EP2-selective and EP4-selective antagonists.  These 
studies demonstrate that the EP4 receptor is the principal receptor that mediates the 
anti-inflammatory effects of PGE2 on human lung macrophages suggesting that EP4 
agonists could be effective anti-inflammatory agents in human lung disease. 
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Methods 
Buffers   
Phosphate buffered saline (PBS) contained (mM): NaCl 137; Na2HPO4.12H2O 8; KCl 
2.7; KH2PO4 1.5.  PIPES buffer contained (mM): PIPES (22), NaCl (110), KCl (5) 
and the pH was titrated to 7.4 with NaOH.  
 
Preparation of compounds 
Stock solutions (10 mM) of PGE2, butaprost (free acid), L-902,688, misoprostol (free 
acid) and indomethacin were prepared in ethanol and stored at ±20 °C.  ONO-AE1-259 
was made up in distilled water (10 mM stock) and stored at ±20 °C.  All antagonists, 
PF-04852946, PF-04418948, CJ-042794 and L-161,982, formerly known as EP4A 
(Machwate et al., 2001), were prepared as stock solutions (10 mM) in dimethyl 
sulphoxide and stored at ±20 °C.  Salbutamol was prepared as a stock solution (10 
mM) dissolved in distilled water and stored at 4 °C.  Roflumilast was prepared as a 
stock solution (10 mM) in dimethyl sulphoxide and stored at ±20 °C. LPS from E. coli 
serotype R515 (Re) was provided as a 1 mg mL-1 stock solution and stored at 4 °C. 
 
Preparation of Streptococcus pneumoniae 
Type 2 S. pneumoniae (Spn) strain D39 was grown and stored as previously described 
(Dockrell et al., 2001). Bacteria were opsonized by resuspending pellets in RPMI-1640 
with 10% anti-pneumococcal immune serum and incubating at 37 °C for 30 min on a 
rotating stand. Pellets were then washed three times in PBS and resuspended in RPMI-
1640 supplemented with 10% FCS (foetal calf serum) without antibiotics. 
 
Lung tissue 
Non-lesional lung tissue was obtained from surgical resections.  Most patients were 
undergoing surgery for carcinoma.  Sixty-two preparations were used in this study 
and these were derived from 31 males and 31 females.  Ages of participants ranged 
from 49 to 88 years with a median age of 71.  The use of lung tissue in this study was 
DSSURYHGE\WKH1DWLRQDO5HVHDUFK(WKLFV¶6HUYLFH5(&UHIHUHQFH15/NW/0657).  
Informed written consent was obtained.  
Macrophage isolation                                                                                                
Lung tissue was chopped with scissors in RPMI-1640 and the tissue filtered over 100 
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ȝPQ\ORQPHVK (Incamesh, Warrington, UK) over a collection vessel.  This cycle of 
chopping and washing was repeated.  The filtrate (100-200 mL) was centrifuged (300 
g, 10 min) at room temperature, the supernatant aspirated and the pellets resuspended 
in 40-50 mL of RPMI-1640 supplemented with 10% FCS, penicillin (25 U mL-1), 
strepWRP\FLQȝJmL-1), JHQWDPLFLQȝJmL-1) and DPSKRWHULFLQ%ȝJP/-1).  
The cell suspensions were inverted several times and left to sediment at 4 oC for 1 h 
according to a protocol modified from Liu et al (1984).  After sedimentation, the 
supernatant was aspirated and the sedimented material was resuspended in 
supplemented RPMI-1640.  This sedimentation step at 4 oC was repeated. The 
sedimented material was resuspended in 30 mL PIPES buffer and centrifuged (300 g, 
10 min, room temperature).  The resulting pellet was resuspended in PIPES buffer and 
the suspension was filtered through nylon mesh before being layered on to a 
discontinuous Percoll gradient. 
One 20 mL Percoll gradient was used for cells harvested from every 5 g of 
lung tissue.  Isotonic Percoll (9 parts Percoll to 1 part 10x PIPES buffer) was diluted 
with PIPES buffer to produce an 80% Percoll gradient. The cell suspension (20 mL) 
was layered onto the gradient and centrifuged (400 g, 20 min, room temperature) 
resulting in a flocculent layer containing macrophages.  The interface was harvested 
and two washes were performed with PIPES buffer (50 mL).  Following 
centrifugation, (488 g, 10 min at room temperature) the resulting cell pellet was 
resuspended in 10 mL of supplemented RPMI-1640 (or for infection experiments, 
supplemented RPMI-1640 without antibiotics).  The cells were counted using a 
haemocytometer.  Macrophages were seeded at 2 x 105 per well in a 24-well cell 
culture plate with 1 mL of supplemented RPMI-1640 (or for infection experiments, 
supplemented RPMI-1640 without antibiotics) and incubated overnight (37 oC, 5% 
CO2). 
The purity of cell suspensions was determined by morphology using cytospins 
(Thermo Shandon Cytospin 3).  Cytospins were stained with Quick-Diff and 
processed DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV  Cell viability was assessed by 
erythrosin-B exclusion.  In this study, macrophage purity was 85±2% and cell 
viability was 92±1%. 
 
Macrophage activation protocol 
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After incubation overnight, medium from the wells was removed and replaced with 
fresh supplemented RPMI-1640 (1 mL) 2 h before the start of the experiment. Where 
pharmacological agents were used the cells were pre-treated with these (30 to 60 min 
at 37 oC, 5% CO2) before addition of stimulus.  When agonists were used, 
macrophages were first incubated with or without indomethacin for 30 min and then 
with or without agonist for a further 30 min before addition of LPS. When antagonists 
were used, cells were incubated first with indomethacin (30 min), then with 
antagonist (1 h) followed by agonist (30 min) before activation.  The cells were 
incubated (37 oC, 5% CO2) for 22 h with the stimulus.  The cell culture supernatants 
were then harvested and centrifuged (488 g, 4 min, room temperature).  The resulting 
supernatants were stored at -80 oC until analysis IRUF\WRNLQHFRQWHQW71)Į and IL-6 
were analysed using commercially-available ELISA kits (RSG kits, eBioscience, 
Hatfield, UK).  PGE2 was also analysed using a commercially-available kit (Cayman 
Chemical Company, Ann Arbor, MI, USA). 
 
Macrophage infection protocol 
After incubation overnight, medium from the wells was removed and replaced with 
fresh supplemented RPMI-1640 without antibiotics (1 mL) 2 h before the start of the 
experiment. Opsonized Type 2 Spn strain D39 were added to the cells at a multiplicity 
of infection (MOI) of 1 or mock infected. The cells were incubated at 4 °C for 1 h to 
maximize bacterial adherence followed by incubation at 37 °C for 3 h for 
internalization. The wells were then washed with PBS and the cell culture medium 
replaced with the re-addition of pharmacological agents as appropriate. The cells were 
incubated at 37 °C until 22 h post-infection. The cell culture supernatants were then 
harvested and stored at -80 oC until analysis for cytokine content. 
 
Assessment of total cell cyclic-AMP 
Macrophages (2 x 105 cells) were incubated (30 min) with or without indomethacin (1 
µM) and then with PGE2 (0.5 to 5 h) in supplemented RPMI-1640 (1 mL). After 
incubation, the supernatants were removed and the cells solubilised by addition of ice-
cold acidified ethanol and snap frozen in liquid nitrogen.  After thawing, the ethanol 
was recovered and centrifuged (13,000 g, 2 min) to pellet any cellular debris.  The 
supernatant was then evaporated off under vacuum using a rotary evaporator.  The 
dried residue was reconstituted in assay buffer (250 µL) and stored at -80 o
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cell cyclic-AMP content was determined using a commercially-available kit (Cayman 
Chemical Company, Ann Arbor, MI, USA).      
 
RT-PCR  
RNA was extracted from purified macrophages (1 to 5 x 106 cells) using Tri-Reagent 
(1 mL).  In order to generate cDNA, samples were processed essentially as described 
elsewhere (Kay et al., 2013).  Amplification of cDNA was performed by PCR using 
conditions and primer pairs for human EP receptor subtypes (Schlötzer-Schrehardt et 
al., 2002; Thorat et al., 2008).  The house-NHHSLQJJHQHȕ-actin, was also amplified.  
Primers were synthesised by Sigma (Poole, UK).  PCR products were sequenced in-
house to ensure that correct amplification had taken place as described in more detail 
elsewhere (Kay et al., 2013). 
  
Materials   
The following were purchased: indomethacin, PGE2, Percoll, salbutamol, Tri-Reagent 
(all Sigma, Poole, UK); gentamicin, penicillin/streptomycin, fungizone, RPMI 1640, 
(Invitrogen, Paisley, UK); butaprost, misoprostol, L-902,688 (Cayman Chemical 
Company, Ann Arbor, MI, USA); L-161,982 (Tocris Bioscience, Bristol, UK); 
roflumilast (Santa Cruz Biotechnology, Heidelberg, Germany);  Quick-Diff (Reagena, 
Toivala, Finland); FCS (Promocell, Heidelberg, Germany); LPS (Enzo Life Sciences, 
Exeter, UK).  
PF-04418948, PF-04852946 and CJ-042794 were obtained from Pfizer Global 
Research & Development (Sandwich, UK).  PF-04418948 will be available 
commercially from Sigma-Aldrich, Tocris and Toronto Research Chemicals Inc 
(North York, ON, Canada).  ONO-AE1-259 was a kind gift from Ono Pharmaceutical 
Company Ltd (Osaka, Japan).  
 
Data analysis 
Antagonist affinity (pKB) was determined by using the Gaddum equation: pKB = 
log(dose ratio ± 1) - log(antagonist concentration) (Kenakin, 1984).  Maximal 
responses (Emax) and potencies (EC50) were determined by non-linear regression 
analysis (GraphPad Prism, version 5.0d, La Jolla, CA, USA).  Statistical significance 
was performed utilizing 6WXGHQW¶Vpaired t-tests or repeated measures ANOVA as 
 10 
appropriate. :KHQDQDO\]LQJGDWDE\$129$SRVWKRFWHVWVZHUHHLWKHU'XQQHWW¶V
WHVWRU7XNH\¶VWHVW Comparisons were considered significant when P < 0.05.  The 
data and statistical analyses described in this paper conform to guidelines provided by 
the journal (Curtis et al., 2015)  
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Results 
PGE2 inhibits cytokine generation from macrophages 
In keeping with previous studies, PGE2 was found to inhibit LPS-induced TNFĮ 
generation from human lung macrophages in a concentration-dependent manner.  This 
experiment was carried out in the absence (Figure 1A) and presence (Figure 1B) of 
the cyclo-oxygenase (COX) inhibitor indomethacin (1 µM).  PGE2 was a more potent 
(EC50; 3.2 ± 0.6 cf 10.8 ± 2.0 nM) and efficacious (Emax; 77 ± 1.8 cf 53.5 ± 2.0 % 
inhibition) inhibitor of LPS-induced TNFĮ generation in the presence of 
indomethacin (Figure 1C).  Moreover, in the presence of indomethacin (1 µM), TNFĮ 
generation by LPS was significantly (P<0.05) higher than in its absence (2657 ± 496 
cf 1648 ±213 pg mL-1; n=13).   
These experiments suggested that macrophages produce PGE2 in response to 
LPS which acts in a paracrine fashion to limit TNFĮ generation.  Further experiments 
confirmed that macrophages generate a small amount of PGE2 spontaneously and 
larger quantities following challenge with LPS (data not shown).  In order to 
eliminate the potentially confounding influence of endogenous PGE2 generation in the 
context of receptor characterizations, in all subsequent functional studies, 
indomethacin was also included.   
In further studies, the effects of PGE2 on LPS-induced IL-6 as well as TNFĮ 
generation were determined (Figure 1D).  PGE2 inhibited TNFĮ and IL-6 generation 
with similar potency (EC50; ~1.6 nM) but PGE2 was less efficacious as an inhibitor of 
IL-6 generation than TNFĮ.  
 
Macrophages express EP2 and EP4 receptors 
Expression of EP receptors by human lung macrophages was determined by RT-PCR.  
The data indicate that human lung macrophages express message for EP2 and EP4 
receptors but do not express message for EP1 or EP3 receptors (Figure 2). 
 
PGE2 increases macrophage cyclic-AMP levels 
Since EP2 and EP4 receptors are G-protein receptors coupled to adenylyl cyclase, we 
investigated whether exposure (30 min) of macrophages to PGE2 (1 µM) induced 
increases in total cell cyclic-AMP.  Our data demonstrated that PGE2 induced 
statistically significant (P<0.05) increases in total cell cyclic-AMP levels over basal 
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(Figure 3).  Further studies demonstrated that PGE2 maintained these increased 
cyclic-AMP levels in macrophages for up to 5 hours (data not shown).  
 
EP4 agonists are far more potent inhibitors than EP2 agonists  
The effects of alternative EP agonists on macrophage function were explored.  The 
effects of misoprostol (non-selective), butaprost (EP2-selective) and L-902,688 (EP4-
selective) on LPS-induced TNFĮ generation from macrophages were investigated.  
The data show that misoprostol (Figure 4A) was about 26-fold less potent than PGE2 
as an inhibitor of TNFĮ generation (Table 1).  The EP4 agonist, L-902,688 (Figure 
4B), was 7-fold more potent than PGE2 as an inhibitor of TNFĮ generation whereas, 
by contrast, the EP2-selective agonist, butaprost (Figure 4C), was over 400-fold less 
potent than PGE2 in this system (Table 2).  In further studies, the effects of an 
alternative EP2-selective agonist, ONO-AE1-259, were determined and ONO-AE1-
259 was about 40-fold less potent than PGE2 (Table 1).  
 
EP4 antagonists reverse the effects of PGE2 
The effects of the antagonists PF-04418948 (EP2-selective) and CJ-042794 (EP4-
selective) were investigated (Murase et al., 2008; af Forselles et al., 2011).  
Macrophages were incubated with either PF-04418948 (300 nM) or CJ-042794 (300 
nM) before incubation with PGE2 and then challenged with LPS.  CJ-042794 
effectively antagonised the PGE2 inhibition of 71)Į generation (Figure 5A).  No 
antagonism of the PGE2 inhibition was seen with PF-04418948 (Figure 5B).   
An alternative EP4-selective antagonist, L-161,982 (Machwate et al., 2001), 
was also evaluated and, in agreement with data obtained with CJ-042794, L-161,982 
(300 nM) was found to be effective as an antagonist (Figure 5C).  An alternative EP2-
selective antagonist, PF-04852946, was also studied.  PF-04852946 is structurally-
distinct from PF-04418948 and about ten-fold more potent than PF-04418948 at EP2 
receptors (Kay et al., 2013).  PF-04852946 (30 nM) was found to be an ineffective 
antagonist of the PGE2 inhibition of TNFĮ generation (data not shown).   
pKB estimates for the antagonism of PGE2 by CJ-042794 and L-161,982 were 
8.77 ± 0.13 (KB, 1.7 nM) and 8.46 ± 0.12 (KB, 3.5 nM), respectively.  These affinities 
are consistent with effects of these compounds at EP4 receptors (Jones et al., 2009). 
In further studies to determine whether a contribution of the PGE2 effect on 
macrophages might be mediated by the EP2 receptor, the effect of a combination of 
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EP2- and EP4-selective antagonists on the PGE2 inhibition was investigated.  The data 
demonstrate that combined use of PF-04418948 (300 nM) and CJ-042794 (300 nM)  
caused marginally greater antagonism of the PGE2 response than CJ-042794 alone 
(Figure 5D).  These data indicate that if the EP2 receptor does contribute to the PGE2 
response in macrophages then the contribution is, at best, minimal.  These data further 
emphasize that EP4 is the principal receptor mediating the anti-inflammatory effects 
of PGE2 on macrophages.  
 
PGE2 LQKLELWV71)ĮJHQHUDWLRQLQGXFHGE\6WUHSWRFRFFXVSQHXPRQLDH 
While LPS is an effective tool to activate macrophages, we also investigated whether 
the response of macrophages to a respiratory pathogen, Streptococcus pneumoniae 
(Spn), could be attenuated by PGE2 (Figure 6).  Preliminary studies indicated that Spn 
induced TNFĮ generation from macrophages in a concentration-dependent fashion 
with maximal levels of release at an MOI of 1 (data not shown).  Further studies 
demonstrated that PGE2 concentration-GHSHQGHQWO\LQKLELWHG71)Į generation 
induced by Spn (MOI of 1).  The effects of alternative agonists, L-902,688  and 
butaprost on Spn-LQGXFHG71)ĮJHQHUDWLRQIURPPDFURSKDJHVZHUHDOVRLQYHVWLJDWHG 
The EP4 agonist, L-902,688 (EC50; ~2 nM) was slightly more potent than PGE2 (EC50; 
~3 nM) DVDQLQKLELWRURI71)ĮJHQHUation whereas, by contrast, the EP2-selective 
agonist, butaprost, was less potent than PGE2. 
 
PGE2 is more effective than either salbutamol or roflumilast  
In further studies we compared the effects of PGE2 with established drugs used in the 
treatment of respiratory diseases.  PGE2 was found to be both more potent and 
HIILFDFLRXVWKDQWKHȕ2-adrenoceptor agonist salbutamol (Figure 7A) as an inhibitor of 
71)ĮJHQHUDWLRQIURPPDFURSKDJHVGULYHQE\/366LPLODr studies with roflumilast, 
an inhibitor of the cyclic-AMP specific phosphodiesterase (PDE) PDE4, 
demonstrated that roflumilast was a considerably weaker inhibitor than PGE2 (Figure 
7B).  Further studies were performed to determine whether roflumilast (30 nM) might 
enhance the effects of PGE2. The data show that, in the context of inhibiting LPS-
LQGXFHG71)ĮJHQHUDWLRQ, the effect of roflumilast on PGE2 was at best additive 
(Figure 7C).  
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Discussion 
In this study, we demonstrate that PGE2 is an effective inhibitor of cytokine 
generation from activated macrophages.  Furthermore, we show that PGE2 acts 
principally through the EP4 receptor to stabilise the pro-inflammatory responses of 
human lung macrophages.  This suggests that in lung diseases in which activated 
macrophages participate, EP4 agonists could be effective anti-inflammatory agents.  
In order to identify which EP receptors are expressed by macrophages a 
number of approaches were adopted.  Evaluation of mRNA expression by RT-PCR 
demonstrated that lung macrophages express both EP2 and EP4 receptors but not EP1 
or EP3 receptors.  These data suggest that EP2 and/or EP4 receptors are involved in 
mediating the effects of PGE2 in human lung macrophages.  This was further 
reinforced by the finding that PGE2 induced increases in total cell cyclic-AMP in 
macrophages.  Because both EP2 and EP4 receptors are known to be coupled to 
adenylyl cyclase, increases in cyclic-AMP are consistent with the expression of EP2 
and/or EP4 receptors in macrophages (Wilson et al., 2004). 
 In attempts to characterize EP receptors further, a range of EP agonists were 
studied for effects on cytokine generation.  The non-selective agonist, misoprostol, 
was about 26-fold less sensitive than PGE2 as an inhibitor of LPS-induced TNFĮ 
generation.  This potency ratio is consistent with an effect of misoprostol at EP4 
receptors since misoprostol is about 29-fold less potent than PGE2 at EP4 receptors 
whereas at EP2 receptors misoprostol is about 7-fold less potent than PGE2 
(Abramovitz et al., 2000).  Alternative agonists were also studied and it was of 
interest that the EP4 agonist L-902,688, was about 7-fold more potent than PGE2.  
This finding provides preliminary evidence that the EP4 receptor is involved in 
mediating the effects of PGE2.  Although EP2-selective agonists were active in this 
system the concentrations of both butaprost and ONO-AE1-259 required for 
inhibition were higher than those usually associated with effects at EP2 receptors. In 
this system, butaprost was over 400-fold less potent than PGE2 whereas at EP2 
receptors butaprost has been reported to be about 18-fold less potent than PGE2 
(Abramovitz et al., 2000).  Also, it is noteworthy that butaprost is known to activate 
EP4 receptors when used at high enough concentrations (Tang et al., 2000; Clarke et 
al., 2004; Wilson et al., 2004; Benyahia et al., 2012). Overall, these data provide 
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strong evidence that the EP4 receptor is responsible for mediating the effects of PGE2 
but evidence for involvement of the EP2 receptor cannot be excluded. 
 In order to obtain a definitive characterization of EP receptors, the effects of 
EP2- and EP4-selective antagonists on the PGE2 response in macrophages were 
evaluated.  It is noteworthy that the EP2 antagonists, PF-04418948 and PF-04852946, 
that were used in this study are highly selective ligands (af Forselles et al., 2011; Kay 
et al., 2013) and considerably superior to AH6809 which until now was the only EP2 
antagonist available.  Indeed, AH6909 has been used in recent studies to invoke a role 
for EP2 receptors 2¶%ULHQHWDO., 2014).  However, AH6809 shows poor selectivity 
and potency such that data generated with this antagonist are unlikely to be reliable 
(Abramovitz et al., 2000; Jones et al., 2009).  Neither of the two EP2 antagonists used 
in this study had any effect on the PGE2 inhibition of 71)Į generation.  By contrast, 
two EP4 antagonists, CJ-042794 (KB; 1.7 nM) and L-161,982 (KB; 3.5 nM) effectively 
reversed the PGE2 inhibition of TNFĮJHQHUDWLRQZLWKDIILQLWLHVconsistent with 
antagonism at EP4 receptors (Jones et al., 2009).  Combining an EP2 antagonist with 
an EP4 antagonist did lead to a marginal rightward shift in the PGE2 concentration 
response curve over that seen with an EP4 antagonist alone.  This could mean that a 
very small component of the PGE2 inhibition is driven by EP2 receptors.  Overall, 
these data provide strong evidence that the principal receptor that mediates the anti-
inflammatory effects of PGE2 in human lung macrophages is the EP4 receptor.  
 The suggestion has been made that the EP4 receptor could be a target for 
respiratory diseases.  This contention has been based largely on recent studies 
showing that PGE2 mediates bronchodilation via the EP4 receptor (Buckley et al., 
2011; Benyahia et al., 2012).  The present study has demonstrated that targeting the 
EP4 receptor may provide desirable anti-inflammatory effects by preventing cytokine 
generation from macrophages.  In this regard, it is of interest that PGE2 attenuated the 
JHQHUDWLRQRIERWK71)ĮDQG,/-6 in human lung macrophages which differs to 
findings reported for mouse alveolar macrophages in which PGE2 LQKLELWHG71)ĮEXW
by contrast potentiated IL-6 generation (Konya et al., 2015).   
The potential therapeutic value of targeting EP receptors is reinforced by the 
finding that PGE2 was effective at attenuating cytokine generation from macrophages 
activated by not only LPS but the respiratory pathogen, S.pneumoniae.  Moreover, it 
is noteworthy that PGE2 was considerably more efficacious and potent than either 
salbutamol or roflumilast as an inhibitor of LPS-induced TNFĮ generation from 
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macrophages.  Bronchodilators such as salbutamol are ȕ2-adrenoceptor agonists that 
may possess some anti-inflammatory activity (Donnelly et al., 2010).  The mechanism 
of action of the PDE4 inhibitor roflumilast is not entirely known although anti-
inflammatory effects have been suggested (Giembycz and Field, 2010). However, our 
data suggest that EP4 agonists are likely to show far greater anti-inflammatory 
potential than HLWKHUȕ2-adrenoceptor agonists or PDE inhibitors.  
 In an allied context, it was notable that the PGE2 response was relatively 
consistent among macrophage preparations (see Supplemental Information, Figure 1).  
This could be important from a therapeutic perspective since the possibility exists that 
factors such as disease state, smoking status and age could influence macrophage 
functionality (Berenson et al., 2006; Hodge et al., 2007; Suzuki et al., 2008).  While 
we were unable to stratify effectively our population according to disease state, we 
were able to stratify according to smoking status and age (see Supplemental 
Information, Figure 1).  There was clearly no difference in the inhibitory response to 
PGE2 among macrophages isolated from smokers, ex-smokers or never smokers.  
Moreover, there was no infuence of age on the inhibitory response to PGE2.  This 
consistency in response could be an advantage when considering the potential of 
targeting the EP4 receptor therapeutically.  
 To conclude, our studies demonstrate that the EP4 receptor is the principal 
receptor that mediates the anti-inflammatory effects of PGE2 in human lung 
macrophages. This suggests that EP4 agonists could be effective anti-inflammatory 
agents in lung diseases that are associated with aberrant macrophage activation.  
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Table 1 EC50 and Emax YDOXHVIRUWKHLQKLELWLRQRI71)ĮJHQHUDWLRQE\(3DJRQLVWV 
 
agonist    EC50 (nM)   Emax (%) 
PGE2     2.1 ± 0.6   77 ± 3 
misoprostol    54 ± 9.1   80 ± 4 
L-902,688    0.3 ± 0.1   63 ± 7 
butaprost    878 ± 340   67 ± 5 
ONO-AE1-259   82 ± 24   43 ± 4 
 
Experimental details relevant to this table can be found in the legend to Figure 4. 
Values are means ± SEM from 5 (misoprostol, L-902,688, ONO-AE1-259), 6 
(butaprost) and 8 (PGE2) experiments. 
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Figure legends 
Figure 1  Effects of PGE2 on cytokine generation from macrophages.  Macrophages 
were pre-incubated without (A) or with (B) indomethacin (1 µM) for 30 min and then 
with or without PGE2 for 30 min before challenge with LPS (1 ng mL-1) for 22 h after 
which supernatants were harvested DQGDVVD\HGIRU71)ĮJHQHUDWLRQ7KHGDWDLQ$
DQG%ZHUHUHZRUNHGDVLQKLELWLRQRIWKHFRQWUROXQEORFNHGUHOHDVHRI71)ĮDQG
this is shown in (C).  In further experiments, macrophages were pre-incubated (30 
min) with indomethacin (1 µM) and then with or without PGE2 for 30 min before 
challenge with LPS (1 ng mL-1) for 22 h and both IL-DQG71)ĮPHDVXUHGLQWKH
supernatants (D).  Values are expressed as the % inhibition of control cytokine 
releases which were 2422 ± 510 pg mL-1 RI71)ĮDQG980 pg mL-1 of IL-6. 
Values are means ± SEM, for 9 (A, B, C) or 6 (D) experiments.  Statistically 
significant (P<0.05) levels of inhibition compared to unblocked control levels are 
indicated by an asterisk. 
 
Figure 2  EP receptor expression in macrophages.  Isolated RNA was converted to 
cDNA by reverse trancriptase (+) and, as a control, this reaction step was also carried 
out in the absence of reverse transcriptase (-).  Amplification of cDNA was performed 
using primers specific for each of the EP receptoUVXEW\SHVDQGȕ-actin.  Expression 
profiles for three macrophage preparations (MAC1, MAC2 and MAC3) are shown.  
No mRNA for EP1 was detected in macrophages but in separate experiments the 
presence of EP1 could be readily demonstrated in several breast cancer cell lines, 
MDA-MB-468, MDA-MB-231 and ZR-75-1 (Kay et al., 2013).  No mRNA for EP3 
was detected but, in separate experiments, EP3 could be detected in the human mast 
cell line, LAD-2 (Kay et al., 2013).  These findings are representative of a total of 5 
different macrophage preparations in excess of 95% purity.  Lanes at either end of 
each gel represent a 100 bp ladder. 
 
Figure 3  Effect of PGE2 on cyclic-AMP.  Macrophages were pre-incubated (30 min) 
with or without indomethacin (indo; 1 µM) and then with or without PGE2 (1 µM) for 
a further 30 min.  After this treatment, the cells were solubilised and total cell cyclic-
AMP levels measured.  Values are means ± SEM for 5 experiments.  Statistically 
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significant (P<0.05) increases in cyclic-AMP over unstimulated control levels are 
indicated by an asterisk. 
 
Figure 4  Effects of EP agonists on macrophages.  Macrophages were pre-incubated 
(30 min) with indomethacin (1 µM) and then with or without either (A) misoprostol, 
(B) L-902,688, (C) butaprost or PGE2 for 30 min before challenge with LPS (1 ng 
mL-1IRUKDIWHUZKLFK71)ĮZDVPHDVXUHGLQWKHVXSHUQDWDQWVValues are 
expressed as the % inhibition of control cytokine release which was 1379 ± 431 pg 
mL-1 RI71)ĮValues are means ± SEM for 5 (A, B) or 6 (C) experiments.  
 
Figure 5  Effects of EP receptor antagonists on PGE2.  Macrophages were pre-
incubated with indomethacin (1 µM) for 30 min and then without or with EP-selective 
antagonists (300 nM) for 1 h and then without or with PGE2 for 30 min before 
challenge with LPS (1 ng mL-1IRUKDIWHUZKLFK71)ĮZDVPHDVXUHGLQWKH
supernatants.  The effects on PGE2 of (A) the EP4-selective antagonist CJ-042794, (B) 
the EP2-selective antagonist PF-04418948, (C) the EP4-selective antagonist L-161,982 
and (D) CJ-042794 with and without PF-04418948 were evaluated.  Values are 
H[SUHVVHGDVWKHLQKLELWLRQRIFRQWURO71)ĮUHOHDVHVZKLFKZHUHLQWKHDEVHQFH 
and presence of antagonist respectively, (A) 2646 ± 562 and 2582 ± 496 pg mL-1, (B) 
2912 ± 532 and 2881 ± 507 pg mL-1, (C) 2756 ± 882 and 2873 ± 862 pg mL-1 and (D) 
2672 ± 972 to 2212 ± 799 pg mL-1.  Values are means ± SEM for 5 (A, B, D) and 6 
(C) experiments, respectively. 
 
Figure 6  Effects of PGE2 and alternative agonists on Spn-induced TNFĮ generation.  
Macrophages were pre-incubated (30 min) with indomethacin (1 µM) and then with 
or without either PGE2, L-902,688 or butaprost for 30 min before challenge with Spn 
02,RIIRUKDIWHUZKLFK71)ĮZDVPHDVXUHGLQWKHVXSHUQDWDQWV9DOXHVDUH
expressed as the % inhibition of the control cytokine release which was 1346 ± 669 
pg mL-1 of 71)ĮValues are means ± SEM for 4 experiments. 
 
Figure 7  Effects of salbutamol and roflumilast on macrophages.  Macrophages were 
pre-incubated (30 min) with indomethacin (1 µM) and then with or without either (A) 
salbutamol, (B) roflumilast or (C) PGE2 in the absence (control) or presence of a 
single concentration of roflumilast (30 nM) for 30 min before challenge with LPS (1 
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ng mL-1) for 22 h after which 71)Įwas measured in the supernatants.  The 
horizontal grid line in (C) shows the inhibition seen with roflumilast alone (22 ± 5% 
inhibition).  Values are expressed as the % inhibition of the unblocked control 71)Į
releases which ranged from 2363 ± 835 to 2208 ± 969 pg mL-1.  Values are means ± 
SEM for 5 (A, B, C) experiments.   
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Figure 3 
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Figure 4 
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Figure 5  
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Figure 6  
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Figure 7  
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